BCL2和BCL3是IGH基因座常见的易位伙伴。

BCL2 and BCL3 are recurrent translocation partners of the IGH locus.

作者信息

Szymanowska Natalia, Klapper Wolfram, Gesk Stefan, Küppers Ralf, Martín-Subero José I, Siebert Reiner

机构信息

Institute of Human Genetics, University Hospital Schleswig-Holstein, Campus Kiel, Christian-Albrechts University, Schwanenweg 24, 24105 Kiel, Germany.

出版信息

Cancer Genet Cytogenet. 2008 Oct 15;186(2):110-4. doi: 10.1016/j.cancergencyto.2008.06.007.

DOI:10.1016/j.cancergencyto.2008.06.007

PMID:18940474

Abstract

Chromosomal translocations affecting the immunoglobulin heavy chain (IGH) locus in chromosomal band 14q32 are the most frequent cytogenetic changes in B-cell lymphomas. We studied the presence of IGH translocations in a consecutively ascertained series of 94 classical Hodgkin lymphomas (cHL) by combined immunofluorescence for CD30 and interphase cytogenetics (FICTION technique). The Hodgkin and Reed-Sternberg cells of a total of 11 of 87 evaluable cases (13%) showed signal patterns indicative of IGH translocations. To identify the translocation partners, these cases were further studied with probes for the MYC, BCL2, BCL6, BCL3, REL/BCL11A, JAK2/PDCD1LG2 (alias PDL2) C14orf43, and C2TA loci. The IGH translocation partner could be identified in four cHL and involved BCL2 and BCL3 in two cases each. Immunohistochemistry in cases with suitable material revealed that tumor cells of the two cHL with IGH/BCL2 fusion and the cHL with IGH/BCL3 fusion expressed the BCL2 and BCL3 protein, respectively. These data indicate that BCL2 or BCL3 are recurrent translocation partners of the IGH locus in cHL; however, most of the translocation partners of IGH translocations in cHL remain to be identified.

摘要

影响14q32染色体带中免疫球蛋白重链（IGH）基因座的染色体易位是B细胞淋巴瘤中最常见的细胞遗传学改变。我们通过联合应用CD30免疫荧光和间期细胞遗传学（FICTION技术），对连续确诊的94例经典型霍奇金淋巴瘤（cHL）进行了IGH易位检测。在87例可评估病例中，共有11例（13%）的霍奇金和里德-斯腾伯格细胞显示出提示IGH易位的信号模式。为了确定易位伙伴，对这些病例进一步用针对MYC、BCL2、BCL6、BCL3、REL/BCL11A、JAK2/PDCD1LG2（别名PDL2）、C14orf43和C2TA基因座的探针进行研究。在4例cHL中可确定IGH易位伙伴，其中2例涉及BCL2，2例涉及BCL3。对有合适材料的病例进行免疫组织化学检测显示, 2例IGH/BCL2融合的cHL和1例IGH/BCL3融合的cHL的肿瘤细胞分别表达BCL2和BCL3蛋白。这些数据表明，BCL2或BCL3是cHL中IGH基因座的常见易位伙伴；然而，cHL中IGH易位的大多数易位伙伴仍有待确定。